Table 1 Study characteristics of the included studies
First author and study year | Study location | Study design | Groups | No. of participants (n) | Sex | Age (Years) | BMI (kg/m2) | Diabetes duration, years | HbA1c %, % |
|---|---|---|---|---|---|---|---|---|---|
Mathieu, C. et al. [20] | Multicenter | Phase 3a, randomized open-label, multicenter | Icodec | 291 | M = 154 (53%) | 59·7 (10·1) | 30·5 (5·0) | 18·0 (9·1) | 8·29 (0·86) |
Glargine U-100 | 291 | M = 150 (52%) | 59·9 (9·9) | 30·0 (5·0) | 16·3 (7·7) | 8·31 (0·90) | |||
Lingvay, I et al. [18] | Multicenter | Randomized active-controlled parallel-group multicenter, multi-national open-label, phase 2, treat-to-target trial | Icodec | ||||||
Tit A | 51 | M = 52.9 | 59.8 (9.1) | 32.3 (4.8) | 9.8 (7.2) | 8.0 (0.7) | |||
Tit B | 51 | M = 54.9 | 61.2 (8.0) | 31.4 (4.7) | 9.6 (4.9) | 8.1 (0.8) | |||
Tit C | 52 | M = 53.8 | 61.4 (8.0) | 30.8 (3.8) | 9.2 (4.4) | 8.2 (0.9) | |||
Glargine U-100 | 51 | M = 52.9 | 60.2 (8.1) | 30.6 (4.7) | 11.8 (6.8) | 8.2 (0.8) | |||
Bajaj, H. S. et al. [19] | Multicenter | Multicenter, open-label, randomized, active-controlled, parallel-group, treat-to-target phase 2 trial | Icodec | ||||||
LD (loading dose) | 54 | M = 39 (72.2) | 62.4 ± 7.2 | 30.2 ± 4.3 | 13.8 ± 7.7 | 7.8 (0.7) | |||
Glargine U-100 | 50 | M = 33 (66.0) | 60.5 ± 7.9 | 30.3 ± 5.0 | 14.8 ± 8.1 | 7.9 (0.7) | |||
Rosenstock, J et al. [17] | Multicenter | Randomized, double-blind double-dummy, phase 2 trial | Icodec | 125 | M = 70 (56%) | 59.7 ± 8.2 | 31.1 ± 4.9 | 10.5 ± 8.4 | 8.09 ± 0.70 |
Glargine U-100 | 122 | M = 69 (56.6%) | 59.4 ± 9.5 | 31.4 ± 4.4 | 8.8 ± 6.1 | 7.96 ± 0.65 |